Merck & Co., Inc. (MRK) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus sits at a beatable bar on revenue (~$16.3B) and KEYTRUDA (~$8.4B), but the stock has already rallied ~17% since the Q1 print, meaning the market has partially priced in execution; the single biggest swing factor is whether KEYTRUDA can sustain momentum without the ~$250M wholesaler timing tailwind that inflated Q1, and whether WINREVAIR and OHTUVAYRE can demonstrate sequential acceleration.

Heading into Q2 2026, Merck's setup is one of a company executing well on a multi-year transformation narrative, with consensus representing a manageable bar rather than a stretched one. Revenue consensus of ~$16.3B implies roughly flat sequential performance versus Q1's $16.3B actual, which is reasonable given management's explicit Q2 guidance flagging a ~$250M KEYTRUDA wholesaler headwind (timing reversal from Q1's benefit) and minimal ENFLONSIA sales due to RSV seasonality. Management's tone on the Q1 call was constructive — they raised the FY2026 revenue midpoint to $66.4B and EPS midpoint to $5.10 (ex-Terns charge), signaling confidence in the underlying business even as the Cidara acquisition charge distorted reported EPS. Estimate revisions have been stable-to-slightly-positive since the Q1 print, with Q2 consensus revenue essentially unchanged at ~$16.3B versus the ~$16.3B post-earnings baseline, suggesting the Street is not chasing the stock higher with aggressive upgrades. The stock's +17% outperformance versus SPY (+5%) and XBI (+12%) since April 30 reflects multiple re-rating on pipeline derisking (sac-TMT TroFuse-005 OS/PFS win in endometrial cancer, OptiTROP-Lung05 PFS win in NSCLC, ASCO Investor Event confidence) rather than pure earnings revision momentum, which means the stock is not cheap heading in. The key wildcard is the tulisokibart Phase 3 ATLAS-UC readout expected in August/September 2026 — a positive result would validate Merck's immunology pivot and could be a meaningful re-rating catalyst, while a miss would raise questions about the post-KEYTRUDA diversification thesis beyond oncology.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a beatable bar on revenue (~$16.3B vs. $16.3B Q1 actual) and KEYTRUDA (~$8.4B), but the Q1 wholesaler timing tailwind of ~$250M will not repeat and creates a modest headwind; WINREVAIR (~$571M consensus) and OHTUVAYRE (~$171M) are the bigger swing factors — both need to show sequential acceleration to validate the new-launch narrative.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data (Sales, EPS – Diluted – Operating, Global – Keytruda (Product), Winrevair – Product, Ohtuvayre, Capvaxive V-116, Gross profit/(loss) – Operating, R&D (Ex. In-process) – Operating, Selling, general and administrative – Operating). MRK Q1 2026 Earnings Call (April 30, 2026) for guidance figures.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Total Revenue & KEYTRUDA)

Pattern: MRK has beaten total revenue consensus in 7 of the last 8 quarters (the one miss in Q1 2025 was GARDASIL-driven); KEYTRUDA has beaten in 6 of 8 quarters, with the two misses (Q3 2025 and Q1 2025) both driven by timing/inventory dynamics rather than underlying demand deterioration. The consistent beat pattern on revenue sets a modestly elevated bar for Q2 2026.

Source: Visible Alpha Consensus and Actuals Data (Sales; Global – Keytruda (Product)).

3. Guidance & Commentary Evolution

Key Takeaway: Management raised FY2026 guidance at the Q1 print (April 30) and has not issued any subsequent formal revision; tone has remained constructive through the ASCO Investor Event (June 1) and AIDS Investor Event (August 3), with no pre-announcement or 8-K guidance change since the Q1 call.

Source: MRK Q1 2026 Earnings Call transcript (April 30, 2026); MRK ASCO Investor Event (June 1, 2026); MRK AIDS Investor Event (August 3, 2026).

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 revenue and KEYTRUDA have been essentially stable since the Q1 print, with only marginal upward drift — the Street is not aggressively revising higher despite the pipeline derisking news flow, suggesting the bar remains beatable rather than stretched; FY2026 consensus has nudged up slightly from the post-Q1 baseline, tracking near the top of management's guidance range.

Estimates have been remarkably stable since the Q1 print, with Q2 revenue and KEYTRUDA consensus moving less than 0.5% in either direction. FY2026 consensus has drifted modestly higher (+0.4% on revenue) and now sits near the top of management's guidance range, suggesting the Street is giving Merck credit for execution without getting ahead of itself. The absence of meaningful upward revision despite strong pipeline news flow (sac-TMT wins, ASCO Investor Event) is a constructive setup — it means the bar is not stretched.

Source: Visible Alpha Consensus and Actuals Data (Sales; Global – Keytruda (Product); Winrevair – Product; EPS – Diluted – Operating($)); as-of date May 5, 2026 used as post-Q1 baseline.

5. Stock Performance

Key Takeaway: MRK has outperformed both XBI (+12%) and the S&P 500 (+5%) by a wide margin since the Q1 2026 earnings print (+17%), driven primarily by multiple re-rating on pipeline derisking (sac-TMT Phase 3 wins, ASCO Investor Event confidence) rather than earnings revision momentum — the stock's move is durable if the pipeline narrative holds, but leaves less room for error on the Q2 print itself.

MRK vs. XBI (Biotech ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (April 30, 2026). Source: Stock Price Data.

• MRK: +17.0% since April 30, 2026 close ($109.18 → $127.77 as of August 4, 2026)
• XBI (Biotech ETF): +12.2% — biotech broadly rallied on positive clinical data flow across the sector
• S&P 500 (SPY): +5.4% — broad market continued its recovery from April tariff-related volatility

Key events driving MRK's outperformance:

• May 22, 2026: sac-TMT TroFuse-005 Phase 3 OS/PFS win in endometrial cancer — first TROP2 ADC to show both OS and PFS benefit vs. chemotherapy; stock surged ~$6 on the day, marking the single largest catalyst since the Q1 print.
• June 1, 2026: ASCO Investor Event — management reiterated >$25B non-risk-adjusted oncology pipeline opportunity by mid-2030s; KEYTRUDA QLEX adoption tracking toward 30–40% peak; sac-TMT positioned as 'cornerstone ADC' across 7+ tumor types.
• June 8, 2026: EVOKE-03 (Trodelvy + KEYTRUDA in 1L PD-L1-high NSCLC) discontinued — a positive read-through for MRK, validating sac-TMT's differentiation vs. Gilead's TROP2 ADC and reinforcing KEYTRUDA's standalone value in lung.
• August 3, 2026: AIDS Investor Event — positive Phase 3 data for islatravir/lenacapavir (ISLEND-1 and ISLEND-2); management quantified HIV franchise opportunity at >$5B non-risk-adjusted by mid-2030s.

Source: Stock Price Data (Yahoo Finance). Sector ETF: XBI (SPDR S&P Biotech ETF) selected as the most relevant benchmark for a large-cap biopharma with a pipeline-driven narrative.

6. Peer Commentaries — Read-Through (Last 60 Days, Q2 2026 Relevant)

Key Takeaway: Peer commentary since the Q1 2026 earnings cycle is broadly constructive for MRK — oncology demand remains robust across the sector, ADC competition is intensifying but sac-TMT's differentiation is being validated by competitor failures (EVOKE-03), and the checkpoint inhibitor market continues to expand; the most direct read-through risk is from AZN's commentary on oral PCSK9 competition for enlicitide.

Note: Only commentary from the current reporting period (Q2 2026) or post-Q1 2026 earnings is included below. Q1 2025 earnings commentary about Q1 2025 results is excluded per the user's instruction.

AstraZeneca (AZN) — Q2 2026 Earnings Call (July 27, 2026)

• Oncology market remains robust: AZN reported total oncology revenues of $14.1B in H1 2026, growing 15% with 18% U.S. growth and 16% European growth. This confirms broad-based oncology demand that benefits KEYTRUDA's continued expansion across indications.
• ADC competition intensifying but differentiation matters: AZN highlighted its wholly-owned TROP2 ADC (with a 'stable linker' design) as 'best in class' vs. ADCs with less stable linkers, citing lower bone marrow toxicity. This commentary implicitly validates sac-TMT's differentiated linker design (bifunctional, pH-sensitive) and reinforces MRK's positioning. AZN CEO Pascal Soriot noted ADC competition from Chinese companies is 'very intense,' consistent with MRK's Kelun partnership strategy.
• Checkpoint inhibitor + ADC combinations: AZN management stated they believe 'combining I/O with ADCs could be transformative across multiple cancers' — a direct read-through supporting MRK's sac-TMT + KEYTRUDA combination strategy (OptiTROP-Lung05 PFS win).
• Oral PCSK9 competition for enlicitide: AZN management confirmed they have seen MRK's 'official first list price' for enlicitide in the U.S. and stated it 'will not change dramatically our own outlook.' AZN expects to have 'a competitive profile versus the compound of Merck' with their own oral PCSK9 data expected in H1 2027. This is a mild negative read-through — enlicitide will face competition, but AZN's data is still ~12 months away, giving MRK a potential first-mover window.
• Next-generation bispecifics: AZN has 16 Phase 3 trials across 8 tumor types for bispecifics, including 5 in combination with ADCs, with ambition to 'replace the current generation of checkpoint inhibitors.' This is a long-term competitive threat to KEYTRUDA's franchise but not a near-term Q2 2026 issue.

Source: AstraZeneca Q2 2026 Earnings Call transcript (July 27, 2026).

Bristol Myers Squibb (BMY) — Q2 2026 Earnings Call (July 30, 2026)

• Oncology market healthy; growth portfolio accelerating: BMY reported total Q2 revenue of ~$13B (+5% YoY) with growth portfolio sales up 14% to $7.6B. Ten products achieved double-digit growth. This confirms the oncology market is healthy and growing, a positive read-through for KEYTRUDA demand.
• Opdivo conversion to Qvantig (subcutaneous): Qvantig (subcutaneous nivolumab) reached $261M in Q2 and is annualizing at >$1B, with Opdivo IV declining 4% due to conversion. This is a direct read-through for KEYTRUDA QLEX — the subcutaneous conversion trend is real and accelerating, validating MRK's QLEX strategy. KEYTRUDA QLEX had $128M in Q1 2026 and received a permanent J-code April 1; Q2 should show meaningful sequential acceleration.
• ADC capabilities expanding: BMY reported 'encouraging Phase 3 data from two isoprene studies' supporting their ADC strategy in solid tumors. The broader ADC market is validating, which is constructive for MRK's sac-TMT and Daiichi Sankyo partnership assets.
• Cell mod launches (Iberdomide, Mezigdomide): BMY is accelerating prelaunch activities for cell mods in multiple myeloma. No direct read-through to MRK's Q2 results, but confirms the hematology market is active and competitive.

Source: Bristol Myers Squibb Q2 2026 Earnings Call transcript (July 30, 2026).

Johnson & Johnson (JNJ) — Q2 2026 Earnings Call (July 15, 2026)

• Oncology market strong; JNJ targeting #1 oncology by 2030: JNJ's Innovative Medicine segment grew 6.8% operationally in Q2, with 8 brands growing double digits. JNJ aims to be the #1 oncology company by 2030 with >$50B in sales. This confirms the oncology market is large and growing, supporting KEYTRUDA's continued expansion.
• Darzalex dominance in multiple myeloma: Darzalex delivered >$4B in Q2 (+17.6%), with 11 points of frontline share gain. No direct MRK read-through, but confirms the hematology market is robust and that first-line penetration is the key growth driver — relevant context for MRK's hematology pipeline (nemtabrutinib, TERN-701, bomedemstat).
• Subcutaneous formulation adoption (Rybrevant Faspro): JNJ highlighted 'rapid uptake in Rybrevant Faspro' as a key growth driver. This is a second data point (alongside BMY's Qvantig) confirming that subcutaneous formulations are gaining rapid adoption — a strong read-through for KEYTRUDA QLEX acceleration in Q2 2026.
• Bladder cancer market expanding: JNJ's In Lexo (intravesical therapy) saw new patient insertions grow 75% QoQ, with nearly 1 in 3 eligible patients starting on an In Lexo regimen. The bladder cancer market is active, which is relevant context for KEYTRUDA's bladder cancer indications (KEYNOTE-B15 filing accepted with August 17 PDUFA date for muscle-invasive bladder cancer).
• KRAS-driven solid tumor acquisition (Firefly Bio): JNJ announced plans to acquire Firefly Bio for a KRAS-targeting platform. This validates MRK's own KRAS strategy (calderasib, Breakthrough Therapy Designation in 1L NSCLC) and confirms the competitive intensity in KRAS-mutant cancers.

Source: Johnson & Johnson Q2 2026 Earnings Call transcript (July 15, 2026).

AbbVie (ABBV) — Q2 2026 Earnings Call (July 31, 2026)

• ADC portfolio expanding; c-met biomarker strategy: ABBV highlighted three ADCs on market (Elahere, Amaryllis, and a new launch) and advancing Tmab A (c-met ADC) in Phase 3 for colon cancer and Phase 2 in ovarian cancer. ABBV's c-met approach is differentiated from TROP2, so limited direct competition to sac-TMT, but confirms the ADC market is broadening.
• Pembrolizumab combination strategy: ABBV is initiating a Phase 2 study of Tmab A plus pembrolizumab in frontline settings. This confirms KEYTRUDA's role as the backbone combination partner of choice across the industry — a positive read-through for KEYTRUDA demand durability.
• PD-1/VEGF bispecific development: ABBV is developing its own PD-1/VEGF program with data expected at World Lung, planning rapid Phase 3 entry as a chemo combo. This is a longer-term competitive threat to KEYTRUDA in lung cancer, but not a Q2 2026 issue. MRK's own MK-2010 (PD-1/VEGF) is Phase 3-ready.
• Oncology revenues down 2.4% operationally: ABBV's oncology segment declined slightly due to Imbruvica erosion, partially offset by Venclexta (+9.6%) and Elahere/Epkinly double-digit growth. The Imbruvica decline is a reminder of the patent cliff risk — relevant context for MRK's own KEYTRUDA LOE planning.

Source: AbbVie Q2 2026 Earnings Call transcript (July 31, 2026).

Gilead Sciences (GILD) — Q1 2026 Earnings Call (May 7, 2026)

• Trodelvy (TROP2 ADC) growing strongly; EVOKE-03 failure is MRK's gain: GILD reported Trodelvy Q1 sales of $402M (+37% YoY), with NCCN Category 1 recommendation for 1L metastatic TNBC. However, the subsequent discontinuation of EVOKE-03 (Trodelvy + KEYTRUDA in 1L PD-L1-high NSCLC, June 8, 2026) is a significant positive read-through for MRK — it validates sac-TMT's differentiated molecular design and reinforces that not all TROP2 ADCs are equivalent. MRK management explicitly used EVOKE-03's failure to highlight sac-TMT's differentiation.
• Islatravir/lenacapavir collaboration update: GILD noted they 'target updates from the Phase 3 ISLEND-1 and 2 trials in collaboration with Merck later this quarter (Q2 2026).' The positive Phase 3 data was subsequently presented at the AIDS Investor Event (August 3, 2026), confirming the collaboration is on track. GILD leads U.S. commercialization; MRK leads ex-U.S.; revenues shared 50/50 up to $2B then 65/35 (GILD/MRK).
• ADC market validation: GILD's CMO stated 'ADCs are one of the most promising modalities in cancer today.' The acquisition of Tubulis (NaPi2b ADC for ovarian cancer) and Arcellx (CAR-T) signals continued industry investment in ADC and cell therapy platforms — constructive for MRK's Daiichi Sankyo partnership and sac-TMT program.
• VEGF/PD-1 combinations: GILD's CMO noted VEGF/PD-1 is 'an interesting mechanism we follow closely' and that combinations need to be 'very targeted to the individual tumor type.' This cautious tone is consistent with MRK's own disciplined approach to MK-2010 (PD-1/VEGF), waiting for additional data before committing to a Phase 3 path.

Source: Gilead Sciences Q1 2026 Earnings Call transcript (May 7, 2026); Gilead RBC Capital Markets Global Healthcare Conference (May 19, 2026).

Pfizer (PFE) — Q1 2026 Earnings Call (May 5, 2026)

• Padcev + pembrolizumab: potential new standard of care in bladder cancer: PFE highlighted EV-304 data showing Padcev + pembrolizumab 'reduces the risk of recurrence or death by nearly 50% in cisplatin-eligible muscle-invasive bladder cancer,' with potential to become the 'new standard of care regardless of cisplatin eligibility.' This is a direct positive read-through for KEYTRUDA — Padcev (PFE) + KEYTRUDA (MRK) is a co-commercialized regimen, and bladder cancer is a growing KEYTRUDA indication. The KEYNOTE-B15 PDUFA date of August 17 is a near-term catalyst.
• Vaccine competition: CAPVAXIVE holding its own: PFE noted Prevnar adult is 'holding share steady at 70% even after many months of competition from Merck.' This confirms CAPVAXIVE (V-116) is gaining share but faces a well-entrenched competitor — consistent with CAPVAXIVE's gradual ramp trajectory.
• SV (sigtolimod vedotin) + pembrolizumab in lung: PFE highlighted 100% response rate in a small PD-L1-high NSCLC cohort for SV + pembrolizumab, with a Phase 3 study recruiting well. This is a longer-term competitive dynamic for KEYTRUDA in lung, but validates the ADC + checkpoint inhibitor combination approach.
• Oncology pipeline confidence: PFE reaffirmed FY2026 guidance ($59.5B–$62.5B revenue) and noted the company is 'off to a really solid start in Q1.' The CFO stated they 'probably would be raising guidance' absent COVID seasonality. Broad pharma sector confidence is constructive for MRK.

Source: Pfizer Q1 2026 Earnings Call transcript (May 5, 2026); Pfizer Goldman Sachs Global Healthcare Conference (June 8, 2026).

7. Material News & Developments

Key Takeaway: The most important development since the Q1 print is the sac-TMT TroFuse-005 OS/PFS win in endometrial cancer (May 2026) — the first TROP2 ADC to show both OS and PFS benefit vs. chemotherapy — which materially de-risks MRK's ADC strategy and accelerates the post-KEYTRUDA growth narrative; the August 17 KEYTRUDA PDUFA date for muscle-invasive bladder cancer is the most immediate near-term catalyst for the Q2 print.

• May 2026 — sac-TMT TroFuse-005 Phase 3 OS/PFS Win (Endometrial Cancer): The first positive global Phase 3 for sac-TMT conducted by Merck demonstrated statistically significant improvement in both OS and PFS vs. chemotherapy in patients with advanced/recurrent endometrial cancer who progressed after platinum and anti-PD-1/L1 therapy. This is the first TROP2 ADC to show both OS and PFS benefit in this setting and the first ADC with randomized Phase 3 data in endometrial cancer. Management characterized sac-TMT as a 'cornerstone ADC.' Implication: Significant pipeline de-risking; accelerates regulatory filing timeline; validates the Kelun partnership.
• May 2026 — Terns Pharmaceuticals Acquisition Closed (~$5.8B charge): The acquisition of Terns Pharmaceuticals (TERN-701, now MK-4208, an oral allosteric BCR::ABL1 inhibitor for CML) closed in May 2026, resulting in a one-time R&D charge of ~$5.8B (~$2.35/share). FDA granted Breakthrough Therapy Designation for MK-4208 in CML patients without T315I mutation previously treated with 2+ TKIs. Post-close diligence confirmed fast kinetics of time to response, with MMR approximately double and DMR 2–3x vs. recent assets. Implication: Distorts Q2 reported EPS; underlying business unaffected. Adds a potential best-in-class CML asset with multibillion-dollar commercial potential.
• May 2026 — OptiTROP-Lung05 Phase 3 PFS Win (NSCLC, ASCO 2026): sac-TMT + pembrolizumab demonstrated highly significant PFS benefit vs. pembrolizumab alone in PD-L1-positive 1L NSCLC (China study). Benefit was consistent across subgroups; OS trend positive but immature. Management noted duration on treatment was approximately double that of pembrolizumab monotherapy. Implication: Validates sac-TMT as a KEYTRUDA combination partner in lung; potential to displace KEYNOTE-189 in KRAS-mutant patients with calderasib combination.
• June 1, 2026 — ASCO Investor Event: Management reiterated >$25B non-risk-adjusted oncology pipeline opportunity by mid-2030s (excluding Terns). KEYTRUDA QLEX adoption rate exiting Q1 was 'mid-single digits,' tracking toward 30–40% peak by end of 2027. WELIREG LITESPARK-022 (adjuvant RCC + KEYTRUDA) PDUFA date June 19; LITESPARK-011 (WELIREG + Lenvima in RCC) PDUFA date October 4. I-DXd PDUFA date October 10 for SCLC. calderasib received Breakthrough Therapy Designation in 1L NSCLC. Implication: Multiple near-term catalysts; management confidence at highest level per CEO.
• June 8, 2026 — EVOKE-03 (Trodelvy + KEYTRUDA in 1L NSCLC) Discontinued: Gilead's Phase 3 KEYNOTE-D46/EVOKE-03 study evaluating sacituzumab govitecan (Trodelvy) + KEYTRUDA vs. KEYTRUDA monotherapy in 1L PD-L1-high NSCLC was discontinued after failing to meet statistical significance for PFS. MRK management explicitly used this to reinforce sac-TMT's differentiation, noting 'not all TROP2 ADCs are the same.' Implication: Significant positive read-through for sac-TMT; validates MRK's molecular design choices and reinforces KEYTRUDA's standalone value in PD-L1-high NSCLC.
• June 19, 2026 — WELIREG + KEYTRUDA FDA Approval (Adjuvant RCC, LITESPARK-022): FDA approved WELIREG in combination with KEYTRUDA for adjuvant treatment of RCC following nephrectomy, based on meaningful improvement in disease-free survival. This is the 12th earlier-stage indication for KEYTRUDA and adds a new revenue stream for WELIREG. Implication: Positive for both KEYTRUDA and WELIREG revenue in H2 2026; validates earlier-stage expansion strategy.
• August 3, 2026 — AIDS Investor Event: Positive Phase 3 Islatravir/Lenacapavir Data (ISLEND-1 & ISLEND-2): Merck and Gilead presented positive Phase 3 data for once-weekly oral islatravir/lenacapavir, demonstrating non-inferior efficacy vs. Bictegravir/FTC/TAF with viral suppression rates >90% (ISLEND-1) and ~95% (ISLEND-2) at Week 48. No treatment-emergent resistance observed. Management quantified the HIV franchise opportunity at >$5B non-risk-adjusted by mid-2030s (Merck's share). Filing to global regulatory authorities planned. Implication: Validates islatravir as a backbone for multiple HIV regimens; potential first approved long-acting oral once-weekly HIV treatment. Not a Q2 2026 revenue driver but a significant long-term catalyst.
• August 17, 2026 — KEYTRUDA PDUFA Date (Muscle-Invasive Bladder Cancer, KEYNOTE-B15): FDA accepted supplemental BLA for KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for cisplatin-eligible muscle-invasive bladder cancer under priority review, with an action date of August 17. If approved, this would be the 12th earlier-stage indication for KEYTRUDA. PFE's EV-304 data showed 47% reduction in risk of recurrence or death. Implication: Imminent near-term catalyst; approval would add a new earlier-stage indication and support KEYTRUDA QLEX adoption in a new setting.
• Enlicitide (Oral PCSK9 Inhibitor) — Potential H2 2026 Approval: CORALreef AddOn Phase 3 data presented at ACC (April 2026) demonstrated statistically significant LDL reduction vs. other oral add-on lipid-lowering therapies on background statin therapy. FDA granted priority review voucher. Management expects potential approval in H2 2026 with active FDA discussions ongoing. AZN confirmed they have seen MRK's list price and are developing a competing oral PCSK9 (data H1 2027). Implication: First-mover advantage in oral PCSK9 if approved; potential multi-billion-dollar cardiometabolic franchise. AZN competition is real but ~12 months away.
• Tulisokibart (TL1A) — Phase 3 ATLAS-UC Readout Expected August/September 2026: The Phase 3 ATLAS-UC study in ulcerative colitis is expected to read out in August/September 2026. Management's ambition is for TL1A to be discussed as a 'foundational immunology node alongside TNF and IL-23.' New Phase 2b trials initiated in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis. Implication: The single biggest binary catalyst for MRK in the near term; a positive result would validate the immunology pivot and could be a significant re-rating event.
• Google Cloud AI Partnership (~$1B multi-year): MRK announced a multi-year partnership with Google Cloud (valued at up to ~$1B) to deploy an agentic AI platform across R&D, manufacturing, commercial, and corporate functions using Gemini Enterprise. Complements existing collaborations with Tempus AI and Mayo Clinic. Implication: Productivity and pipeline acceleration lever; signals AI is now a formal strategic pillar. Not a near-term revenue driver.

Sources: MRK Q1 2026 Earnings Call (April 30, 2026); MRK ASCO Investor Event (June 1, 2026); MRK AIDS Investor Event (August 3, 2026); MRK Summary Knowledge; Gilead Q1 2026 Earnings Call (May 7, 2026); Pfizer Q1 2026 Earnings Call (May 5, 2026).

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells were filed in the period since the Q1 2026 earnings print; all transactions are routine RSU vesting events (Form 4 code M = exercise/conversion, F = tax withholding) and annual equity grant awards (code A) — there is no meaningful insider signal heading into Q2 2026 earnings.

All Form 4 filings since April 30, 2026 reflect: (1) routine RSU vesting and associated tax-withholding sales (codes M/F) around the Q1 earnings date (April 29–30), (2) annual equity grant awards (code A) filed May 5–7 for the broad executive team, and (3) quarterly phantom stock accruals for non-employee directors (codes A, May 29 and June 30). No open-market purchases (code P) or discretionary sales (code S) were filed by any insider during the period. The absence of open-market activity — in either direction — is the norm for large-cap pharma and does not carry a negative signal.

Notable Transactions (Open-Market Buys / Discretionary Sales Only)

None identified. All transactions in the period are routine compensation-related events (RSU vesting, tax withholding, annual equity grants, director phantom stock accruals). No open-market buys or discretionary sells were filed.

Summary of Routine Transactions (Selected, Post-Q1 Earnings)

Source: Insider Transaction Data (SEC Form 4 filings, April 29 – July 1, 2026). All transactions reflect Form 4 codes: A = Award/Grant, M = Exercise/Conversion of derivative security, F = Payment of exercise price or tax liability by delivering or withholding securities. No open-market buys (code P) or discretionary sales (code S) were identified in the period.

Appendix: Key Upcoming Catalysts

Sources: MRK Q1 2026 Earnings Call (April 30, 2026); MRK ASCO Investor Event (June 1, 2026); MRK AIDS Investor Event (August 3, 2026); MRK Summary Knowledge; Visible Alpha Consensus and Actuals Data; Stock Price Data (Yahoo Finance); AstraZeneca Q2 2026 Earnings Call (July 27, 2026); Bristol Myers Squibb Q2 2026 Earnings Call (July 30, 2026); Johnson & Johnson Q2 2026 Earnings Call (July 15, 2026); AbbVie Q2 2026 Earnings Call (July 31, 2026); Gilead Sciences Q1 2026 Earnings Call (May 7, 2026); Pfizer Q1 2026 Earnings Call (May 5, 2026); Insider Transaction Data (SEC Form 4 filings).